Plasma heparin activity in 11 patients undergoing open-heart surgery was measured by comparing thrombin time of patient plasma to thrombin time of plasma containing known heparin concentrations. Although all patients received 300 units/kg of heparin, their initial plasma heparin levels varied significantly, from 1.8 units/ml in lighter patients to 3 units/ml in heavier patients. During hypothermia (25' C), heparin decay was insignificant. A t 37OC, heparin decayed a t a rate between 0.37 and 2.01 units/ml/hr. This decay was significantly faster in those patients with higher initial posthypothermia plasma heparin levels.
on clotting,' 12 a precise, practical method of evaluating circulating heparin levels during cardiopulmonary bypass in mail has been lacking. As a result, over 30 protocols for heparin administration are in use in this country.:' Among these, dosages of heparin, and of protamine used to reverse heparin, vary considerably," with consequent excesses and deficits of both. Bull and coworkers4 attempted to overcome this problem by using a dose-response curve in which clotting time is a function of heparin dose, but they still encountered marked variations in clotting time from patient to patient. We therefore undertook the following study to pre-When heparin was reversed with a protamine dose based on circulating plasma heparin levels, the mean difference between the predicted and the actual residual heparin activity was 0.025 unitdml. Heparin levels vary widely because of the influence of temperature on decay rates and because the space into which heparin is distributed is not simply proportional t o weight. Evaluation and reversal of plasma heparin activity require ongoing analysis rather than any 1 dosage protocol. cisely assay plasma heparin levels in patients undergoing cardiopulmonary bypas, and to formulate an accurate method for reversing heparin with protamine. were serially diluted 1 : l with veronal buffer. and then 1 : l with unheparinized pooled based on a 2-hour heparin half-life was given.
MATERIALS AND METHODS

**Fibrometer, Becton Dickinson Company, Cockys-
"Pump-prime contains 1000 ml Normosol,@ 500 nil dextran-40, 22.5 mg mannitol. and 2200 units heparin.
ville, Maryland.
iG5 ml in females.
STotal protamine dose = (1 mg/kg) ( e ) -"," '""' ( t -hours after the last heparin dose).
Statistical Methods.-Decay rates were derived from the slope of the regression lines ielating heparin levels to elapsed time. Regression lines and correlation coefficients ( r ) were derived by least-squares analysis of variance. Significance of the regression was computed by Student's t-test.
RESULTS
The thrombin time control curves (fig 1) demonstrate that in-vitro heparinization of plasma prolonged thrombin time. The invitro assay is consistent within %0.05 unit/ ml below heparin concentrations of 2 units/ ml and kO.1 unit/ml from 2 to 4 units/ml. In-vitro dilution ( 1 : 1) of heparinized controls with pump-prime, plasma, or Ringer's solution resulted in a proportional reduction in thrombin times, but in-vitro dilution ( 1 : 1) with distilled water shortened control thrombin times by more than a factor of 6.
There was a consistent pattern of heparin activity during open-heart surgery. Figure  2 shows a typical patient's record. Following a loading dose of heparin, plasma heparin levels usually peaked out of the range of the assay, but fell within 30 minutes to between 3 and 5 units/ml. After instituting bypass, heparin levels fell further because of hemodilution with pump-prime and then plateaued in association with hypothermia. With each redose of heparin during hypothermia, the plateau increased. Following rewarming, heparin levels declined until heparin was reversed with protaniine. 4) was insignificant (0.21 units/ml/hr f 0.12 S D ) . After rewarming to 37" C, heparin levels declined linearly at a significant (p<O.Ol) rate between 0.37 and 2.01 units/ ml/hr. These decay rates were directly proportional (p<O.Ol; r = 0.93) to the initial heparin levels following rewarming.
Heparin decay during hypothermia (fig
At the end of bypass, 8 patients received a protamine dose calculated to reverse approximately 95 percent of the assayed circulating heparin. The mean difference between the predicted and actual residual heparin level was 0.025 units/ml & 0.09 SE. This represents a mean error in protamine dose of only 1.3 mg f 2.7 SE/patient, or about a 2 percent error. The BART returned to within 4 percent of preoperative control values, and no heparin activity was detectable after administration of the remainder of our conventional protamine dose. 
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DISCUSSION
Many methods of measuring heparin levels exist. Of these, only the microelectrophoresis method of Jaques' measures heparin directly, but it requires 5 or more hours to complete. The BART,I0 activated coagulation time,5 activated partial thromboplastin time,11 Bason,? and thromboelastogram" are only semiquantitative methods. Other clotting-time tests measure heparin quantitatively. Of these, factor lo,, analysis" is a complex multiple-stage test, and the diluted activated partial thromboplastin time' was significantly prolonged by incubation of controls for 30 minutes a t 21" C.ll The thrombin time bioasay described in this study was quite satisfactory. It is easy, precise and quantitative, is relatively unaffected by hemodilution, could be performed in duplicate in 6 to 12 minutes. and the cost was reasonable.
Although all patients received equal mg/ kg loading heparin doses, after initiating bypass their plasma levels were not equal but were instead proportional to weight. The 2 heaviest patients had over 66 percent higher levels than the 2 lightest patients. Heavier patients thus demonstrated a heparin space which was relatively smaller per kg body weight than that of the lighter patients. More uniform initial heparin levels might be achieved by administering loading doses calculated on the basis of lean body weight rather than by actual weight.
Heparin decay during hypothermia is relatively insignificant. Because decay is so profoundly reduced and heparin redoses only serve to raise the level of the plateau, redoses during hypothermia could be markedly reduced or eliminated entirely. Ideally, redoses should be based on monitored heparin levels.
Previous studies of heparin activity during normothermial,x revealed an exponential pattern of decay. Our patients had linear decay patterns after rewarming to 37" C, which may be the result of exposure to hypothermia. Alternatively, the linear segments may simply represent short portions of an exponential decay curve. This might explain why patients with higher heparin levels after rewarming had more rapid decay rates than those with low levels.
Neutralizing heparin with 1 mg protamine per mg of measured circulating heparin avoids the use of excess protamine. While excess protamine is known to act as an anticoagulant in-vitro, Ellison has disputed the possibility of this effect inviva.':! 1. 5 Ellison advocates a protamine dose of 1 mg/kg of heparin given during bypass to avoid heparin rebound, which he observed in 3/6 patients receiving half that dose.'3 1 4 T h e clinical significance of Ellison's findings regarding heparin rebound and the benign nature of protamine is disputed by other workers. Guffin and coworkers,"; in a study of 60 patients, showed that postoperative bleeding was decreased by approximately 50 percent by reducing protamine from the dose recommended by Ellison to the lower dose with which Ellison observed rebound.
In a study of 92 patients whose heparin was not neutralized, Castanedal7 showed a return of Lee-White clotting time to normal within 4 hours after bypass. He observed no cases of unexpected postoperative bleeding. Other adverse effects of protamine include myocardial depression, 80 percent reduction in platelet count,'" ' 9 and sludging due to red cell aggregation with consequently increased vascular resistance,' 7 including an increase in pulmonary artery pressure of up to 121 percent and pulmonary venous pressure of 134 percent."
While further studies of the relevance of heparin rebound and protamine excess would be useful, the weight of the evidence supports the use of the method of heparin neutralization presented in this study, in which no more protamine is given than is necessary to reverse the heparin.
CONCLUSIONS
The results of this study contain clinically important implications regarding the use of heparin for open-heart surgery. In order to achieve uniform initial plasma levels, loading doses of heparin should probably be based on lean body weight. Heparin decay during hypothermia is relatively insignificant. Therefore, redoses during this period may be reduced or omitted. Following rewarming, heparin decay becomes significant, but the decay rates are highly variable from patient to patient. Heparin can be accurately neutralized by 1 mg protamine per mg circulating heparin. Because of the influence of temperature and patient weight on heparin activity during bypass, accurate control and reversal of heparin requires ongoing analysis rather than any 1 dosage protocol. leagues on a thoughtful and significant contribution to an area of medicine that has had much of its practice based on "visceral" data and anecdotal information. I would like to emphasize a few aspects of their paper and draw some comparisons with information presently available in the literature.
The most important point to emphasize is their finding of a variable patient response to fixed heparin doses by quantitation of the thrombin time. We all learned in basic pharmacology that any group of individuals has a "bell-shaped curve" response to drugs, but our clinical practice as physician5 has not shown our understanding of this basic concept. As anesthesiologists we titrate drugs based on response probably more than most areas of medicine, but this demonstration by Dr. Cohen seems somehow overdue.
His information supports in a quantitative way recent data by Bull and his colleagues,' who measured heparin activity hy the less exact, but nonetheless clinically meaningful, technic of activated clotting time. The individual patient variation in that study was further accentuated by a variety of rigid protocols for heparin administration. The findings by Dr. Cohen that the obese patient has a relatively smaller heparin space emphasizes the importance of lean body mass for drug distribution and that this is important for heparin as well. There are, however, some areas in this report that are a t odds with reports by previous investigators.
The use of the thrombin clotting time by Dr. Cohen showed a marked cessation of heparin metabolism a t 26 to 28" C. Bull's group' found such a small and unpredictable decline in metabolism of heparin that it was not considered significant at 30°, using the activated clotting time. Wright and coworkers,2 in a rather gross estimation of heparin activity, did demonstrate marked cessation of metabolism in dogs and man with hypothermia, as have others, hut Dr. Cohen has quantitated this plateau more accurately. Although temperatures were not exactly comparable, it would follow that metabolism of heparin, like other drugs, would be slowed, even though Bull's study did not show this.
The use of the calculated amount of heparin remaining after bypass to determine the protamine required to neutralize it yielded insignificant errors in actual residual heparin in the present study. This led to a considerably reduced protamine dose. Ellison and colleagues? looked a t the enects of excess protamine on the coagulation system and found that doses of 800 mg/70 kg produced minimal effects on coagulation. However, they did not measure a platelet count, which has been shown by Gans and Castaneda and others to be reduced following protamine administration.
Ellison:{.-' used, among other tests, the protamine titration method of quantitating the remaining heparin for neutralization. All patients who received protamine ( about 0.5 mg) for each 1 mg of heparin given presumably a result of heparin decay) dcmonstrated anticoagulation ( heparin rebound ) by their criteria. In 316 with low-dose protamine, clinical bleeding required more protamine up to 5 hours following the initial reversal.
Pat,ients in Dr. Cohen's report, however, received an even lower protamine/cumulative heparin dose (0.3 mg/l m g ) , and none had postoperative bleeding complications. To add to the controversy, Guffin's group" recently evaluated low-dose protamine based on heparin decay and found a marked reduction in chest drainage and operating time along with improved coagulation studies when compared with a 1 mg/l mg protamine-to-heparin ratio. This information is in direct conflict with data from Ellison and others.
The question remains as to why such diverse results can be obtained with similar operations, drugs, and patient populations.
